Kenneth Allen Myszkowski Arrowhead Pharmaceuticals, Inc. (ARWR) insider trading activity

Kenneth Allen Myszkowski is Chief Financial Officer of ARROWHEAD PHARMACEUTICALS, INC.. Currently has a direct ownership of 455,433 shares of ARWR, which is worth approximately $9.09 Million. The most recent transaction as insider was on Jan 07, 2025, when has been sold 18,000 shares (Common Stock) at a price of $19.7 per share, resulting in proceeds of $354,600. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 455K

13.69% 3M change

3.37% 12M change

Total Value Held $9.09 Million

Kenneth Allen Myszkowski Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 07 2025	SELL Open market or private sale	$354,600 $19.7 p/Share	18,000 Reduced 3.8%	455,433 Common Stock
Jan 06 2025	SELL Open market or private sale	$540,351 $19.89 p/Share	27,167 Reduced 5.43%	473,433 Common Stock
Jan 04 2025	BUY Grant, award, or other acquisition	-	100,000 Added 16.65%	500,600 Common Stock
Mar 06 2024	SELL Open market or private sale	$1,407,600 $35.19 p/Share	40,000 Reduced 9.08%	400,600 Common Stock
Jan 05 2024	SELL Open market or private sale	$561,868 $34.89 p/Share	16,104 Reduced 3.53%	440,600 Common Stock
Jan 04 2024	BUY Grant, award, or other acquisition	-	75,000 Added 14.11%	456,704 Common Stock
Jun 27 2023	SELL Open market or private sale	$543,000 $36.2 p/Share	15,000 Reduced 3.78%	381,704 Common Stock
Jan 04 2023	BUY Grant, award, or other acquisition	-	60,000 Added 13.14%	396,704 Common Stock
Dec 29 2022	SELL Open market or private sale	$1,225,000 $40.0 p/Share	30,625 Reduced 8.34%	336,704 Common Stock
Jan 05 2022	SELL Open market or private sale	$2,496,400 $62.41 p/Share	40,000 Reduced 7.94%	464,005 Common Stock
Jan 01 2022	BUY Grant, award, or other acquisition	-	60,000 Added 10.64%	504,005 Common Stock
Jan 12 2021	SELL Open market or private sale	$116,721 $81.0 p/Share	1,441 Reduced 0.32%	444,005 Common Stock
Jan 11 2021	SELL Open market or private sale	$939,589 $81.02 p/Share	11,597 Reduced 2.54%	445,446 Common Stock
Jan 06 2021	SELL Open market or private sale	$2,196,425 $71.72 p/Share	30,625 Reduced 6.28%	457,043 Common Stock
Jan 01 2021	BUY Grant, award, or other acquisition	-	60,000 Added 10.96%	487,668 Common Stock
Nov 09 2020	SELL Open market or private sale	$3,021,422 $69.45 p/Share	43,505 Reduced 9.23%	427,668 Common Stock
Nov 09 2020	BUY Exercise of conversion of derivative security	$632,563 $14.54 p/Share	43,505 Added 8.45%	471,173 Common Stock
Oct 20 2020	SELL Open market or private sale	$1,576,131 $54.04 p/Share	29,166 Reduced 6.38%	427,668 Common Stock
Oct 20 2020	BUY Exercise of conversion of derivative security	$179,371 $6.15 p/Share	29,166 Added 6.0%	456,834 Common Stock

KAM

Kenneth Allen Myszkowski

Chief Financial Officer

Pasadena, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ARWR shares.

Notify only if

Value

Insider Trading

Get notified when an Arrowhead Pharmaceuticals, Inc. insider buys or sells ARWR shares.

Notify only if

Operation

Value

Type

News

Receive news related to ARROWHEAD PHARMACEUTICALS, INC.

Track Activities on ARWR

Account